Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids for Amphetamine Dependence
NCT02952196Phase 2Withdrawn
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in amphetamine use disorder (3 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Assessing amphetamine craving at 3 days. Planned start Nov 2016; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
amphetamine use disorder
Beyond the preview
Go deeper on NCT02952196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952196.